Literature DB >> 17047025

Obestatin is not elevated or correlated with insulin in children with Prader-Willi syndrome.

Won Hah Park1, Yoo Joung Oh, Gae Young Kim, Sang Eun Kim, Kyung-Hoon Paik, Sun Ju Han, An Hee Kim, Su Hyun Chu, Eun Kyung Kwon, Seon Woo Kim, Dong-Kyu Jin.   

Abstract

CONTEXT: Obestatin is a peptide hormone derived from the proteolytic cleavage of ghrelin preprohormone. In Prader-Willi syndrome (PWS), the levels of total ghrelin (TG) and acylated ghrelin (AG) are increased, and these hormones are regulated by insulin.
OBJECTIVE: Our objective was to analyze the changes in the obestatin levels after glucose loading and to characterize the correlations of obestatin with TG, AG, and insulin.
DESIGN: Plasma obestatin, TG, AG, and insulin levels were measured in PWS children (n = 15) and controls (n = 18) during an oral glucose tolerance test.
SETTING: All subjects were admitted to the Samsung Medical Center.
INTERVENTIONS: An oral glucose tolerance test was performed after an overnight fast. MAIN OUTCOME MEASURES: The plasma levels of obestatin, TG, AG, and serum insulin were measured at 0, 30, 60, 90, and 120 min after glucose challenge, and areas under the curves (AUCs) were calculated.
RESULTS: No significant difference in AUC of the plasma obestatin was found between the PWS children and normal obese controls (P = 0.885), although AUC of AG (P = 0.002) and TG (P = 0.003) were increased in the PWS children. Moreover, There was a negative correlation between the AUC of AG and AUC of insulin both in PWS (r = -0.432; P = 0.049) and in controls (r = -0.507; P = 0.016). However, AUC of obestatin was not significantly correlated with AUC of insulin (in PWS, r = 0.168 and P = 0.275; in controls, r = -0.331 and P = 0.09).
CONCLUSIONS: Our results indicate that plasma obestatin is not elevated in PWS children and is not regulated by insulin both in PWS children and in obese controls.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047025     DOI: 10.1210/jc.2006-0754

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Acute effect of smoking on plasma Obestatin levels.

Authors:  Asterios Kukuvitis; Marios Froudarakis; Stavros Tryfon; Argyris Tzouvelekis; Maria Saroglou; Nikolaos Karkavitsas; Demosthenes Bouros
Journal:  Tob Induc Dis       Date:  2010-01-07       Impact factor: 2.600

2.  Plasma obestatin and ghrelin levels in subjects with Prader-Willi syndrome.

Authors:  Merlin G Butler; Douglas C Bittel
Journal:  Am J Med Genet A       Date:  2007-03-01       Impact factor: 2.802

Review 3.  Ghrelin-Derived Peptides: A Link between Appetite/Reward, GH Axis, and Psychiatric Disorders?

Authors:  Alexandra Labarthe; Oriane Fiquet; Rim Hassouna; Philippe Zizzari; Laurence Lanfumey; Nicolas Ramoz; Dominique Grouselle; Jacques Epelbaum; Virginie Tolle
Journal:  Front Endocrinol (Lausanne)       Date:  2014-10-27       Impact factor: 5.555

4.  Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader-Willi syndrome.

Authors:  R J Kuppens; G Diène; N E Bakker; C Molinas; S Faye; M Nicolino; D Bernoux; P J D Delhanty; A J van der Lely; S Allas; M Julien; T Delale; M Tauber; A C S Hokken-Koelega
Journal:  Endocrine       Date:  2015-05-20       Impact factor: 3.633

Review 5.  Obesity management in Prader-Willi syndrome: current perspectives.

Authors:  Antonino Crinò; Danilo Fintini; Sarah Bocchini; Graziano Grugni
Journal:  Diabetes Metab Syndr Obes       Date:  2018-10-04       Impact factor: 3.168

6.  Prader-Willi syndrome: an update on obesity and endocrine problems.

Authors:  Su Jin Kim; Sung Yoon Cho; Dong-Kyu Jin
Journal:  Ann Pediatr Endocrinol Metab       Date:  2021-12-31

Review 7.  Do patients with Prader-Willi syndrome have favorable glucose metabolism?

Authors:  Yanjie Qian; Fangling Xia; Yiming Zuo; Mianling Zhong; Lili Yang; Yonghui Jiang; Chaochun Zou
Journal:  Orphanet J Rare Dis       Date:  2022-05-07       Impact factor: 4.303

8.  In vivo neuroimaging evidence of hypothalamic alteration in Prader-Willi syndrome.

Authors:  Stephanie S G Brown; Katherine E Manning; Paul Fletcher; Anthony Holland
Journal:  Brain Commun       Date:  2022-09-09

Review 9.  Obesity in Prader-Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches.

Authors:  G Muscogiuri; L Barrea; F Faggiano; M I Maiorino; M Parrillo; G Pugliese; R M Ruggeri; E Scarano; S Savastano; A Colao
Journal:  J Endocrinol Invest       Date:  2021-04-23       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.